Skip to main content
Springer Nature Link
Account
Fig. 1 | Clinical Pharmacokinetics

Fig. 1

From: Lack of Effect of 12-Week Treatment with Risankizumab on the Pharmacokinetics of Cytochrome P450 Probe Substrates in Patients with Moderate to Severe Chronic Plaque Psoriasis

Fig. 1The alternative text for this image may have been generated using AI.

Mean plasma concentration–time profiles for the cytochrome P450 (CYP) probe drugs and metabolites alone and in the presence of risankizumab 150 mg administered subcutaneously every 4 weeks for 12 weeks. Open symbols indicate CYP probe drugs and metabolites alone on day 1; closed symbols indicate CYP probe drugs and metabolites on day 98 after 12-weeks of treatment with risankizumab

Back to article page